Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2

Neurology
B W van OostenChris Polman

Abstract

There is evidence that treatment with an antibody to tumor necrosis factor alpha (TNF alpha) improves an animal model of multiple sclerosis (MS) and is beneficial in two systemic inflammatory disease in humans, but there are no reports about anti-TNF treatment of MS. Therefore, we treated two rapidly progressive MS patients with intravenous infusions of a humanized mouse monoclonal anti-TNF antibody (cA2) in an open-label phase I safety trial and monitored their clinical status, gadolinium-enhanced brain magnetic resonance imaging (MRI), and peripheral blood and cerebrospinal fluid (CSF) immunologic status. We did not notice any clinically significant neurologic changes in either patient. The number of gadolinium-enhancing lesions increased transiently after each treatment in both patients. CSF leukocyte counts and IgG index increased after each treatment. The transient increase in the number of gadolinium-enhancing lesions that followed each infusion of cA2 together with the increase in cells and immunoglobulin in the CSF of each patient suggest that the treatment caused immune activation and an increase in disease activity. These results suggest that further use of cA2 in MS is not warranted and that studies of other agents t...Continue Reading

Citations

Jul 21, 2010·Archives of Dermatology·Rachel KleinJonathan Dunham
Jan 27, 2009·Inflammatory Bowel Diseases·D C Burger, T H J Florin
Sep 18, 2010·Inflammatory Bowel Diseases·H HamzaogluR J Farrell
Jun 6, 2007·Der Nervenarzt·A-M BeyerK P Wandinger
Aug 30, 2012·Zeitschrift für Rheumatologie·A Rubbert-Roth, H-F Petereit
Dec 14, 2004·Journal of Neurology·Jorge Correale, Andrés Villa
Sep 20, 2005·Journal of Neurology·Fred Lublin
Mar 28, 2009·Journal of Neurology·Tjalf Ziemssen
Mar 28, 2009·Journal of Neurology·Alexander WinkelmannUwe Klaus Zettl
Nov 26, 2010·Journal of Neurology·Ming-Ou Lu, Jie Zhu
Apr 25, 2006·Modern Rheumatology·Nobuyuki MiyasakaKatsumi Eguchi
Jul 6, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Sara L Montgomery, William J Bowers
Apr 10, 2013·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Rhoanne C McPherson, Stephen M Anderton
Sep 13, 2013·Current Neurology and Neuroscience Reports·Erin E LongbrakeAnne H Cross
Jan 25, 2012·Journal of Ophthalmic Inflammation and Infection·Alice Kim, Norman Saffra
Dec 5, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Sabeen Lulu, Emmanuelle Waubant
Feb 21, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Dimitrios Karussis
Apr 23, 2004·Trends in Molecular Medicine·Bert A 't HartErwin Blezer
Apr 17, 2002·Lancet·Alastair Compston, Alasdair Coles
Apr 27, 2000·Immunology Today·H DrakesmithP Beverley
Aug 6, 2002·Controlled Clinical Trials·UNKNOWN WGET Research Group
Sep 7, 2001·Current Opinion in Immunology·L Steinman
Jan 23, 1999·Current Opinion in Immunology·A P Cope
Sep 11, 2002·Cytokine & Growth Factor Reviews·Evangelos T AndreakosMarc Feldmann
Sep 11, 2002·Cytokine & Growth Factor Reviews·George Kollias, Dimitris Kontoyiannis
Aug 30, 2001·Trends in Immunology·G MartinoL Adorini
Nov 17, 2001·International Immunopharmacology·K A Brown
Jun 6, 2012·Cell Research·Changsheng Du, Xin Xie

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.